Accelerated Approval For PCSK9 Inhibitors Not Up For Discussion, FDA Tells Panel
Executive Summary
FDA asked its advisory committee not to discuss accelerated approval for Sanofi/Regeneron's Praluent and Amgen's Repatha; panelists wanted to discuss the idea anyway, however, given uncertainty around the reliability of LDL-cholesterol as a surrogate.
You may also be interested in...
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class
Regeneron/Sanofi and Amgen stress the strengths of the Phase III PCSK9 development programs at the American College of Cardiology annual meeting. The mechanism of action holds appeal, but development is taking place at a time of skepticism about surrogate CV markers, following failed trials of other drugs.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.